Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The lancet Gastroenterology & hepatology. 2018; 3: 383–403.
Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016; 65: 700–10.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67: 1560–99.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67: 370–98.
Lampertico P, Vigano M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon alpha–2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut. 2013; 62: 290–8.
Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa–2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682–95.
Biron CA. Interferons alpha and beta as immune regulators—a new look. Immunity. 2001; 14: 661–4.
Ma H, Zhang HH, Wei L. Frequency of T-cell FoxP3(+) Treg and CD4(+)/CD8(+) PD–1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon. Chin Med J (Engl). 2013; 126: 267–73.
Fletcher SP, Chin DJ, Gruenbaum L, et al. Intrahepatic Transcriptional Signature Associated with Response to Interferon-alpha Treatment in the Woodchuck Model of Chronic Hepatitis B. Plos Pathog. 2015; 11: e1005103.
Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012; 12: 125–35.
Swiecki M, Colonna M. Type I interferons: diversity of sources, production pathways and effects on immune responses. Current opinion in virology. 2011; 1: 463–75.
Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol. 2013; 58: 205–9.
Micco L, Peppa D, Loggi E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol. 2013; 58: 225–33.
Tang TJ, Kwekkeboom J, Mancham S, et al. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J Hepatol. 2005; 43: 45–52.
Cho H, Kang H, Lee HH, Kim CW. Programmed Cell Death 1 (PD–1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA–4) in Viral Hepatitis. Int J Mol Sci. 2017; 18.
Said EA, Al-Reesi I, Al-Riyami M, et al. Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection. Plos One. 2016; 11: e0158265.
Said EA, Al-Reesi I, Al-Riyami M, et al. A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression. Plos One. 2016; 11: e0153191.
Boltjes A, Movita D, Boonstra A, Woltman AM. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol. 2014; 61: 660–71.
Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology. 2005; 128: 138–46.
Karlmark KR, Weiskirchen R, Zimmermann HW, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology. 2009; 50: 261–74.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24: 289–93.
Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology. 2009; 137: 1151–60, 60 e1–7.
Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol. 2011; 54: 209–18.
Cooper A, Tal G, Lider O, Shaul Y. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol. 2005; 175: 3165–76.
Hosel M, Quasdorff M, Wiegmann K, et al. Not interferon, but interleukin–6 controls early gene expression in hepatitis B virus infection. Hepatology. 2009; 50: 1773–82.